Cipla Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Cipla Ltd is ₹ 1325 as of 04 May 10:48 . The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 yearsThe P/E Ratio of Procter & Gamble Health Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 yearsThe Market Cap of Procter & Gamble Health Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Cipla Ltd for the Dec '25 is ₹ 7280 crore as compare to the Sep '25 revenue of ₹ 7858 crore. This represent the decline of -7.35% The revenue of Procter & Gamble Health Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cipla Ltd for the Dec '25 is ₹ 1185 crore as compare to the Sep '25 ebitda of ₹ 2163 crore. This represent the decline of -45.21% The ebitda of Procter & Gamble Health Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 674.56 crore over 7 quarters. This represents a CAGR of -27.22% The net profit of Procter & Gamble Health Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 0 % on June 2024 . This represents a CAGR of -100.00% over 9 yearsThe Dividend Payout of Procter & Gamble Health Ltd changed from 88.52 % on March 2025 to 214.75 % on June 2024 . This represents a CAGR of 19.39% over 5 years .

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Cipla Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Cipla Ltd or Procter & Gamble Health Ltd?

Market cap of Cipla Ltd is 105,811 Cr while Market cap of Procter & Gamble Health Ltd is 8,622 Cr

What are the key factors driving the stock performance of Cipla Ltd and Procter & Gamble Health Ltd?

The stock performance of Cipla Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Procter & Gamble Health Ltd?

As of May 4, 2026, the Cipla Ltd stock price is INR ₹1309.9. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5194.55.

How do dividend payouts of Cipla Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Cipla Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.